Enanta Pharmaceuticals Inc (ENTA) FinancialsENTAFinancialEnanta Pharmaceuticals Inc

Evaluating the bottom line, Enanta Pharmaceuticals Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -120.04%, while the net margin is -135.81%. These profitability ratios, combined with a Return on Equity (ROE) of -70.12%, provide a clear picture of how effectively ENTA converts its operational activities into shareholder value.

In the context of the broader market, ENTA competes directly with industry leaders such as EYPT and TKNO. With a market capitalization of $396.11M, it holds a significant position in the sector. When comparing efficiency, ENTA's gross margin of 100.00% stands against EYPT's 100.00% and TKNO's 37.73%. Such benchmarking helps identify whether Enanta Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Enanta's total revenue has shown growth, with Q1 2026 revenue at $18,615,000, up from $14,607,000 in Q4 2024. However, the company has reported consistent net losses, with Q2 2026 net income at -$13,091,000.